CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Bioventures Opportunities G. Yk Sells 3,250,000 Shares

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $0.10, for a total transaction of $325,000.00. Following the sale, the insider now directly owns 22,620,783 shares of the company’s stock, valued at $2,262,078.30. This represents a 12.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

CERo Therapeutics Trading Up 52.4 %

CERO stock opened at $0.29 on Friday. The business’s 50-day moving average is $0.10 and its 200 day moving average is $0.35. CERo Therapeutics Holdings, Inc. has a 12-month low of $0.06 and a 12-month high of $12.80.

CERo Therapeutics (NASDAQ:CERO) last released its earnings results on Wednesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.